Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-7058 + SHR-A2102 + SHR-1316
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a triple combination therapy developed by Shandong Suncadia Medicine Co., Ltd. (a subsidiary of Jiangsu Hengrui Pharmaceuticals) for the treatment of advanced malignant solid tumors, particularly those harboring KRAS G12C mutations. The regimen consists of HRS-7058, a small molecule inhibitor of the KRAS G12C mutant protein; SHR-A2102, an antibody-drug conjugate (ADC) targeting Nectin-4 with a topoisomerase I (TOP1) inhibitor payload; and SHR-1316 (adebrelimab), a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1). By combining targeted inhibition of the KRAS pathway, cytotoxic delivery via an ADC, and immune checkpoint blockade, the therapy aims to overcome resistance mechanisms and enhance anti-tumor efficacy in solid tumors.
- Other names
- HRS-7058 + SHR-A2102 + adebrelimab
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)KRAS (Kirsten rat sarcoma viral oncogene homolog)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on HRS-7058 + SHR-A2102 + SHR-1316.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-7058 + SHR-A2102 + SHR-1316.